Q-omics provides the consensus-scored OXNAD1 profile across patient tissues and cancer cell-line models. OXNAD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, OXNAD1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, OXNAD1 RNA expression shows 20,735 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, KIRC, and ACC as cancer lineages where OXNAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OXNAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OXNAD1 survival associations across molecular data types. OXNAD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OXNAD1 RNA expression–survival associations across cancer types. High OXNAD1 expression shows unfavorable associations in ACC, SARC and UCEC, but favorable associations in READ, KIRP and THYM. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for OXNAD1 RNA expression.
This table summarizes OXNAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OXNAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OXNAD1 shows lower tumor expression in KIRC and THCA and higher tumor expression in STAD, BLCA, LUAD and UCEC. The KIRC box plot shows higher OXNAD1 RNA expression in normal versus tumor tissue (log2 FC = −1.097, t-test p < 0.001).
This table shows molecular features associated with OXNAD1 in patient tissues and cancer cell lines. In patient samples, OXNAD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OXNAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
